Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema

Purpose To assess the effectiveness of a switch to faricimab in individuals affected by DME and previously treated with aflibercept. Methods In this retrospective, single-center study, DME patients previously treated with at least 3 injections of aflibercept then switched to faricimab were enrolled. Best corrected visual acuity (BCVA) and central subfield thickness (CST) were recorded at baseline, at the time of the switch and at 6 months follow-up. At transition to faricimab, patients were categorized as "good visual responders" (≥ 5 letters from baseline) or "poor visual responders" (